These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30060600)

  • 1. Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes.
    Ochieng J; Nangami G; Sakwe A; Moye C; Alvarez J; Whalen D; Thomas P; Lammers P
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion.
    Gerst F; Wagner R; Kaiser G; Panse M; Heni M; Machann J; Bongers MN; Sartorius T; Sipos B; Fend F; Thiel C; Nadalin S; Königsrainer A; Stefan N; Fritsche A; Häring HU; Ullrich S; Siegel-Axel D
    Diabetologia; 2017 Nov; 60(11):2240-2251. PubMed ID: 28791439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The "thrifty" gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance.
    Goustin AS; Abou-Samra AB
    Cell Signal; 2011 Jun; 23(6):980-90. PubMed ID: 21087662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fetuin-A in newly detected type 2 diabetes mellitus as a marker of non-alcoholic fatty liver disease.
    Yamasandhi PG; Dharmalingam M; Balekuduru A
    Indian J Gastroenterol; 2021 Dec; 40(6):556-562. PubMed ID: 34950996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of fetuin-A in atherosclerosis associated with diabetic patients.
    Singh M; Sharma PK; Garg VK; Mondal SC; Singh AK; Kumar N
    J Pharm Pharmacol; 2012 Dec; 64(12):1703-8. PubMed ID: 23146032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From infancy to aging: Biological and behavioral modifiers of Fetuin-A.
    Robinson KN; Teran-Garcia M
    Biochimie; 2016 May; 124():141-149. PubMed ID: 26740309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fetuin-A with diverse functions and multiple mechanisms on human health.
    Icer MA; Yıldıran H
    Clin Biochem; 2021 Feb; 88():1-10. PubMed ID: 33245873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking TLR4-NF-κB pathway protects mouse islets from the combinatorial impact of high fat and fetuin-A mediated dysfunction and restores ability for insulin secretion.
    Mukhuty A; Fouzder C; Kundu R
    Mol Cell Endocrinol; 2021 Jul; 532():111314. PubMed ID: 33989718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hepatokine fetuin-A disrupts functional maturation of pancreatic beta cells.
    Gerst F; Kemter E; Lorza-Gil E; Kaiser G; Fritz AK; Nano R; Piemonti L; Gauder M; Dahl A; Nadalin S; Königsrainer A; Fend F; Birkenfeld AL; Wagner R; Heni M; Stefan N; Wolf E; Häring HU; Ullrich S
    Diabetologia; 2021 Jun; 64(6):1358-1374. PubMed ID: 33765181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum fetuin-A concentration predicts glycaemic outcomes in people with prediabetes: a prospective study from eastern India.
    Dutta D; Mondal SA; Kumar M; Hasanoor Reza AH; Biswas D; Singh P; Chakrabarti S; Mukhopadhyay S
    Diabet Med; 2014 Dec; 31(12):1594-9. PubMed ID: 24975463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fetuin-A secretion from β-cells leads to accumulation of macrophages in islets, aggravates inflammation and impairs insulin secretion.
    Mukhuty A; Fouzder C; Kundu R
    J Cell Sci; 2021 Nov; 134(21):. PubMed ID: 34643217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does fetuin-A mediate the association between pro-inflammatory diet and type-2 diabetes mellitus risk?
    Toprak K; Görpelioğlu S; Özsoy A; Özdemir Ş; Ayaz A
    Nutr Hosp; 2022 Mar; 39(2):383-392. PubMed ID: 34841880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fetuin-A (alpha 2HS glycoprotein) modulates growth, motility, invasion, and senescence in high-grade astrocytomas.
    Nangami GN; Sakwe AM; Izban MG; Rana T; Lammers PE; Thomas P; Chen Z; Ochieng J
    Cancer Med; 2016 Dec; 5(12):3532-3543. PubMed ID: 27882696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature.
    Dabrowska AM; Tarach JS; Wojtysiak-Duma B; Duma D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):352-9. PubMed ID: 25916279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fetuin-A and the cardiovascular system.
    Mori K; Emoto M; Inaba M
    Adv Clin Chem; 2012; 56():175-95. PubMed ID: 22397032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans.
    Stefan N; Hennige AM; Staiger H; Machann J; Schick F; Kröber SM; Machicao F; Fritsche A; Häring HU
    Diabetes Care; 2006 Apr; 29(4):853-7. PubMed ID: 16567827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients?
    Berezin A
    Diabetes Metab Syndr; 2016; 10(3):169-70. PubMed ID: 26869171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No Independent Association of Circulating Fetuin-A with Insulin Sensitivity in Young Women.
    Reif S; Moschko S; Gar C; Ferrari U; Hesse N; Sommer NN; Seißler J; Lechner A
    Horm Metab Res; 2020 Nov; 52(11):809-814. PubMed ID: 32767281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of hepatic alpha-2-HS-glycoprotein transcription by testosterone via androgen receptor activation.
    Voelkl J; Pakladok T; Lin Y; Viereck R; Lebedeva A; Kukuk D; Pichler BJ; Alesutan I; Lang F
    Cell Physiol Biochem; 2014; 33(6):1911-20. PubMed ID: 25011927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Fetuin-A and Risk of Type 2 Diabetes: A Mendelian Randomization Analysis.
    Kröger J; Meidtner K; Stefan N; Guevara M; Kerrison ND; Ardanaz E; Aune D; Boeing H; Dorronsoro M; Dow C; Fagherazzi G; Franks PW; Freisling H; Gunter MJ; Huerta JM; Kaaks R; Key TJ; Khaw KT; Krogh V; Kühn T; Mancini FR; Mattiello A; Nilsson PM; Olsen A; Overvad K; Palli D; Quirós JR; Rolandsson O; Sacerdote C; Sala N; Salamanca-Fernández E; Sluijs I; Spijkerman AMW; Tjonneland A; Tsilidis KK; Tumino R; van der Schouw YT; Forouhi NG; Sharp SJ; Langenberg C; Riboli E; Schulze MB; Wareham NJ
    Diabetes; 2018 Jun; 67(6):1200-1205. PubMed ID: 29523632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.